<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2017-06-23" updated="2019-12-02">
  <drugbank-id primary="true">DB13615</drugbank-id>
  <name>Mifamurtide</name>
  <description>Mifamurtide is an immunomodulator with antitumor activity via activation of macrophages and monocytes. Also called L-MTP-PE, mifamurtide may be a liposomal form of of the active ingredient MTP-PE, which is a synthetic, less pyrogenic, and longer-acting derivative of muramyl dipeptide (MDP). MDP is a motif present in all gram-positive and gram-negative bacterial walls that is recognized by different signalling molecules and activators such as nucleotide-binding and oligomerization domain (NOD)-like receptors (NLRs) and toll-like receptors present in macrophages and monocytes. The overall result of MDP recognition leads to the production of proinflammatory cytokines and promotion of bactericidal and tumoricidal effects [A31745]. As a liposomal formulation, mifamurtide demonstrates an enhanced tumoricidal effect and improved safety profile [A31745].&#13;
&#13;
Mifamurtide is marketed in Europe as Mepact for intravenous infusion. It is administered as an adjuvant therapy to postoperative combination chemotherapy in pediatric, adolescent or adult patients with high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection. In the US, it is currently under investigation that holds orphan drug status for the treatment of osteosarcoma [A31746].&#13;
&#13;
Osteosarcoma is the most common primary malignant bone tumor that usually arises in the metaphyses of long bone in children and adolescents [A31744]. The standard therapy for osteosarcoma is comprised of macroscopic surgical resection and multi-agent chemotherapy consisting of doxorubicin, cisplatin, high-dose methotrexate with leucovorin rescue, and ifosfamide [A31744]. While about 90% of patients with newly diagnosed osteosarcoma may achieve complete remission from first-line therapies, the prognosis is still poor for patients with non-metastatic osteosarcoma with lower 5-year event-free survival. In a large, randomized, open-label, multicenter, phase III trial, the treatment of mifamurtide in conjunction with three- or four-drug combination chemotherapy (doxorubicin, cisplatin, and high-dose methotrexate with, or without, ifosfamide) was associated with significant improvement in survival rates and good tolerance [A31746]. The adverse events (AEs) associated with mifamurtide were generally mild to moderate in severity [A31748].</description>
  <cas-number>838853-48-8</cas-number>
  <unii>1LM890Q4FY</unii>
  <average-mass>1277.515</average-mass>
  <monoisotopic-mass>1276.74102124</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A31744</ref-id>
        <pubmed-id>21226638</pubmed-id>
        <citation>Ando K, Mori K, Corradini N, Redini F, Heymann D: Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011 Feb;12(2):285-92. doi: 10.1517/14656566.2011.543129.</citation>
      </article>
      <article>
        <ref-id>A31745</ref-id>
        <pubmed-id>20596505</pubmed-id>
        <citation>Kager L, Potschger U, Bielack S: Review of mifamurtide in the treatment of patients with osteosarcoma. Ther Clin Risk Manag. 2010 Jun 24;6:279-86.</citation>
      </article>
      <article>
        <ref-id>A31746</ref-id>
        <pubmed-id>20481644</pubmed-id>
        <citation>Frampton JE: Mifamurtide: a review of its use in the treatment of osteosarcoma. Paediatr Drugs. 2010 Jun;12(3):141-53. doi: 10.2165/11204910-000000000-00000.</citation>
      </article>
      <article>
        <ref-id>A31748</ref-id>
        <pubmed-id>24134216</pubmed-id>
        <citation>Venkatakrishnan K, Liu Y, Noe D, Mertz J, Bargfrede M, Marbury T, Farbakhsh K, Oliva C, Milton A: Pharmacokinetics and pharmacodynamics of liposomal mifamurtide in adult volunteers with mild or moderate hepatic impairment. Br J Clin Pharmacol. 2014 Jun;77(6):998-1010. doi: 10.1111/bcp.12261.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L1203</ref-id>
        <title>EMA Summary of product characteristics: Mepact, INN-mifamurtide</title>
        <url>http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000802/WC500026565.pdf</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Indicated in children, adolescents and young adults for the treatment of high-grade, resectable, non-metastatic osteosarcoma after macroscopically complete surgical resection, typically in combination with post-operative multi-agent chemotherapy [L1203].</indication>
  <pharmacodynamics>Mifamurtide stimulates the innate immunity by activating monocytes and macrophages. Within hours following administration of mifamurtide in healthy adults or patients with osteosarcoma NOS, elevated plasma levels of proinflammatory molecules, such as TNF-α, IL-6, and IL-1β, and other indicators of immune stimulation like C-reactive protein and neopterine were observed [A31745]. _In vivo_ administration of mifamurtide in rat and mouse model resulted in inhibition of tumour growth of lung metastasis, skin and liver cancer, and fibrosarcoma [L1203]. In addition, increased disease-free survival rate was demonstrated when mifamurtide was given as an adjuvant in dog models of osteosarcoma and hemangiosarcoma. Administration of mifamurtide was associated with transient neutropenia, usually when used in conjunction with chemotherapy. Pronounced inflammatory responses are uncommon [L1203].</pharmacodynamics>
  <mechanism-of-action>It was discovered that tumor necrosis could be promoted by factors released by the host’s immune system (e.g. macrophages) in response to the endotoxins or bacterial products [A31745]. Mifamurtide is referred to as MTP-PE or L-MTP-PE (in case of the liposomal formulation), which is a fully synthetic derivative of muramyl dipeptide (MDP), which is a motif within the peptidoglycan polymer in the cell wall of bacteria. &#13;
&#13;
MDP stimulates the immune system by being recognized by different pattern recognition molecules and receptors, such as nucleotide-binding oligomerization domain (NOD) 2 receptor and toll-like receptor (TLR). Similarly, mifamurtide acts as a ligand for TRL4 and NOD2. Involved in the innate immunity, NOD2 is an intracellular MDP sensor that is primarily expressed on monocytes, dendritic cells, and macrophages. It possesses an amino-terminal caspase recruitment domain, which is required to trigger nuclear factor-kappaB (NF-κB) signaling [A31745]. Activation of intracellular signaling transduction pathway NF-κB can promote inflammation and release of antimicrobial peptides, resulting in the production of pro-inflammatory cytokines like interleukin-1β (IL-1β), interleukin-6 (IL-6), and TNF-α, and other molecules such as chemokines and adhesion molecules [A31745]. Upon binding to TLR4, mifamurtide may activate extracellular-signal-regulated kinase 1/2 (ERK 1/2), nuclear factor-kappa B (NF-κB) and adaptor protein (AP)-1 [A31744]. Mifamurtide may also activate NLRP3, which is an essential component of the inflammasome, a protein complex that promotes the cleavage of procaspase 1 into its active form. Active caspase 1 further activates pro-inflammatory cytokines like IL-1β [A31745]. Furthermore, mifamurtide induces the expression of adhesion molecules including lymphocyte function-associated antigen (LFA)-1, intracellular adhesion molecule (ICAM)-1, and human leukocyte antigen (HLA)-DR [A31744]. Mifamurtide may interact with interferon (IFN)-γ to up-regulate tumoricidal activity [A31744].&#13;
&#13;
Upon intravenous administration, lipophilic mifamurtide is selectively phagocytosed by monocytes and macrophages followed by subsequent degradation of liposomal vesicles by the phagocytic cells. Then, MTP-PE is released into the cytosol where it interacts with Nod2 and activates the macrophages and monocytes [A31744]. Mifamurtide exerts a tumoricidal action via the same signalling pathway as MDP but with greater superiority because the lipophilic properties of MTP-PE cause higher cell uptake via passive transfer through the cytoplasmic membrane [A31744]. Incorporation of MTP-PE into liposomal structures allows better safety profile and more efficient distribution to the liver, spleen, and lungs after intravenous administration [A31744].</mechanism-of-action>
  <toxicity>There have been no reports of overdose with mifamurtide. Signs and symptoms that were associated with higher doses and/or were dose limiting were not life-threatening, and included fever, chills, fatigue, nausea, vomiting, headache and hypotension or hypertension [L1203]. In cases of suspected overdose, appropriate supportive care is recommended. Gastrointestinal toxicity associated with nausea, vomiting and loss of apetite from mifamurtide therapy is commonly observed. &#13;
&#13;
Mifamurtide was not mutagenic and did not cause teratogenic effects in rats and rabbits. Embryotoxic effects were observed only at maternal toxic levels. There is no evidence of mifamurtide generating harmful effects on male or female  reproductive organs. Studies assessing reproductive function, perinatal toxicity and carcinogenicity have not been performed [L1203].</toxicity>
  <metabolism>Metabolism of liposomal MTP-PE has not been studied in humans [L1203]. The liposomes are mainly phagocytosed by the cells of the reticuloendothelial system (RES) [A31745].</metabolism>
  <absorption>Due to rapid clearance from plasma, administration of mifamurtide is associated with a very low serum concentration of total (liposomal and free) drug. The mean AUC was 17.0 ± 4.86 h x nM and peak plasma concentration (Cmax) was 15.7 ± 3.72 nM following intravenous administration of 4 mg mifamurtide in healthy adult subjects [L1203]. Variability in AUC and Cmax is reported to be low [A31748].</absorption>
  <half-life>Following intravenous administration of 4 mg mifamurtide in healthy adult subjects, the half life was 2.05 ± 0.40 hours. In pediatric and adult patients with psteosarcoma, the half life was 2.04 ± 0.456 hours after intravenous infusion of 2 mg/m^2 [L1203].</half-life>
  <protein-binding/>
  <route-of-elimination>As there was no quantifiable urinary excretion of mifamurtide and renal impairment has no clinically significant impact on drug pharmacokinetics, renal clearance is not expected to contribute to the total systemic clearance of mifamurtide [A31748].</route-of-elimination>
  <volume-of-distribution>The mean volume of distribution at steady state (Vss) of total mifamurtide ranged from 225 to 28.7 healthy subjects after 4 mg intravenous infusion [A31748]. There is no evidence of accumulation of L-MTP-PE or free MTP-PE (non-liposome-associated) [A31745].</volume-of-distribution>
  <clearance>The clearance from the plasma is rapid [L1203]. Following 4 mg intravenous infusion, the mean clearance rate of total mifamurtide in healthy subjects ranged from 565 to 569 mL/min [A31748].</clearance>
  <salts/>
  <synonyms>
    <synonym language="spanish" coder="">Mifamurtida</synonym>
    <synonym language="english" coder="usan">Mifamurtide</synonym>
  </synonyms>
  <products>
    <product>
      <name>Mepact</name>
      <labeller>Takeda France Sas</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/000802</ema-product-code>
      <ema-ma-number>EU/1/08/502/001</ema-ma-number>
      <started-marketing-on>2009-03-06</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form/>
      <strength>4 mg</strength>
      <route>Intravenous</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Mepact</name>
      <ingredients>Mifamurtide</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Acids, Acyclic</category>
      <mesh-id>D000144</mesh-id>
    </category>
    <category>
      <category>Adjuvants, Immunologic</category>
      <mesh-id>D000276</mesh-id>
    </category>
    <category>
      <category>Alcohols</category>
      <mesh-id>D000438</mesh-id>
    </category>
    <category>
      <category>Amino Acids, Peptides, and Proteins</category>
      <mesh-id>D000602</mesh-id>
    </category>
    <category>
      <category>Amino Sugars</category>
      <mesh-id>D000606</mesh-id>
    </category>
    <category>
      <category>Antineoplastic and Immunomodulating Agents</category>
      <mesh-id/>
    </category>
    <category>
      <category>Carbohydrates</category>
      <mesh-id>D002241</mesh-id>
    </category>
    <category>
      <category>Glycerophosphates</category>
      <mesh-id>D005994</mesh-id>
    </category>
    <category>
      <category>Glycerophospholipids</category>
      <mesh-id>D020404</mesh-id>
    </category>
    <category>
      <category>Glycoconjugates</category>
      <mesh-id>D006001</mesh-id>
    </category>
    <category>
      <category>Glycopeptides</category>
      <mesh-id>D006020</mesh-id>
    </category>
    <category>
      <category>Hydroxy Acids</category>
      <mesh-id>D006880</mesh-id>
    </category>
    <category>
      <category>Immunologic Factors</category>
      <mesh-id>D007155</mesh-id>
    </category>
    <category>
      <category>Lipids</category>
      <mesh-id>D008055</mesh-id>
    </category>
    <category>
      <category>Membrane Lipids</category>
      <mesh-id>D008563</mesh-id>
    </category>
    <category>
      <category>Muramic Acids</category>
      <mesh-id>D009112</mesh-id>
    </category>
    <category>
      <category>Peptides</category>
      <mesh-id>D010455</mesh-id>
    </category>
    <category>
      <category>Phosphatidic Acids</category>
      <mesh-id>D010712</mesh-id>
    </category>
    <category>
      <category>Phospholipids</category>
      <mesh-id>D010743</mesh-id>
    </category>
    <category>
      <category>Sugar Acids</category>
      <mesh-id>D013400</mesh-id>
    </category>
    <category>
      <category>Sugar Alcohols</category>
      <mesh-id>D013402</mesh-id>
    </category>
    <category>
      <category>Sugar Phosphates</category>
      <mesh-id>D013403</mesh-id>
    </category>
    <category>
      <category>Triose Sugar Alcohols</category>
      <mesh-id>D000073999</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans and other mammals</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form/>
      <route>Intravenous</route>
      <strength>4 mg</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="L03AX15">
      <level code="L03AX">Other immunostimulants</level>
      <level code="L03A">IMMUNOSTIMULANTS</level>
      <level code="L03">IMMUNOSTIMULANTS</level>
      <level code="L">ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries/>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB13615.pdf?1517504502</msds>
  <patents/>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00864</drugbank-id>
      <name>Tacrolimus</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tacrolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11693</drugbank-id>
      <name>Voclosporin</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Voclosporin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Icosapent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Mesalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Nabumetone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Ketorolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tenoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tolmetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00533</drugbank-id>
      <name>Rofecoxib</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Rofecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Piroxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Fenoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00580</drugbank-id>
      <name>Valdecoxib</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Valdecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Diclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Sulindac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Flurbiprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Etodolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Mefenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Naproxen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Phenylbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Meloxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Carprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Diflunisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Salicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Meclofenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Oxaprozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Ketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Balsalazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01050</drugbank-id>
      <name>Ibuprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Ibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01283</drugbank-id>
      <name>Lumiracoxib</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Lumiracoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Magnesium salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Salsalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Choline magnesium trisalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Antrafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Aminophenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tiaprofenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02224</drugbank-id>
      <name>Taxifolin</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Taxifolin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03585</drugbank-id>
      <name>Oxyphenbutazone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Oxyphenbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04552</drugbank-id>
      <name>Niflumic acid</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Niflumic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04725</drugbank-id>
      <name>Licofelone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Licofelone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Nimesulide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04812</drugbank-id>
      <name>Benoxaprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Benoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04817</drugbank-id>
      <name>Metamizole</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Metamizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04828</drugbank-id>
      <name>Zomepirac</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Zomepirac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05095</drugbank-id>
      <name>Cimicoxib</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Cimicoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Lornoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Aceclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06737</drugbank-id>
      <name>Zaltoprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Zaltoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07402</drugbank-id>
      <name>Azapropazone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Azapropazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07477</drugbank-id>
      <name>Felbinac</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Felbinac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08439</drugbank-id>
      <name>Parecoxib</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Parecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08797</drugbank-id>
      <name>Salicylamide</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Salicylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08940</drugbank-id>
      <name>Kebuzone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Kebuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08942</drugbank-id>
      <name>Isoxicam</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Isoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08951</drugbank-id>
      <name>Indoprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Indoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08955</drugbank-id>
      <name>Ibuproxam</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Ibuproxam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08976</drugbank-id>
      <name>Floctafenine</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Floctafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08981</drugbank-id>
      <name>Fenbufen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Fenbufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08984</drugbank-id>
      <name>Etofenamate</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Etofenamate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08991</drugbank-id>
      <name>Epirizole</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Epirizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09084</drugbank-id>
      <name>Benzydamine</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Benzydamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09212</drugbank-id>
      <name>Loxoprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Loxoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Dexibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Dexketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Droxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09216</drugbank-id>
      <name>Tolfenamic acid</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tolfenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09217</drugbank-id>
      <name>Firocoxib</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Firocoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09218</drugbank-id>
      <name>Clonixin</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Clonixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09285</drugbank-id>
      <name>Morniflumate</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Morniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Propacetamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09295</drugbank-id>
      <name>Talniflumate</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Talniflumate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11455</drugbank-id>
      <name>Robenacoxib</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Robenacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11466</drugbank-id>
      <name>Tepoxalin</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tepoxalin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11518</drugbank-id>
      <name>Flunixin</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Flunixin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12399</drugbank-id>
      <name>Polmacoxib</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Polmacoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Nitroaspirin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12480</drugbank-id>
      <name>Betulinic Acid</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Betulinic Acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Indobufen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12610</drugbank-id>
      <name>Ebselen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Ebselen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13001</drugbank-id>
      <name>Tinoridine</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tinoridine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13167</drugbank-id>
      <name>Alclofenac</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Alclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13217</drugbank-id>
      <name>Fentiazac</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Fentiazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13232</drugbank-id>
      <name>Suxibuzone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Suxibuzone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13286</drugbank-id>
      <name>Bumadizone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Bumadizone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13314</drugbank-id>
      <name>Alminoprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Alminoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13317</drugbank-id>
      <name>Flunoxaprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Flunoxaprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13364</drugbank-id>
      <name>Feprazone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Feprazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13371</drugbank-id>
      <name>Difenpiramide</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Difenpiramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13407</drugbank-id>
      <name>Nifenazone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Nifenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13432</drugbank-id>
      <name>Lonazolac</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Lonazolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13481</drugbank-id>
      <name>Tenidap</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Tenidap.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13501</drugbank-id>
      <name>Bendazac</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Bendazac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13514</drugbank-id>
      <name>Pranoprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Pranoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13524</drugbank-id>
      <name>Propyphenazone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Propyphenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13527</drugbank-id>
      <name>Proglumetacin</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Proglumetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Guacetisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13544</drugbank-id>
      <name>Ethenzamide</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Ethenzamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Carbaspirin calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13629</drugbank-id>
      <name>Mofebutazone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Mofebutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13649</drugbank-id>
      <name>Proquazone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Proquazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13657</drugbank-id>
      <name>Benorilate</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Benorilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13722</drugbank-id>
      <name>Pirprofen</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Pirprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13783</drugbank-id>
      <name>Acemetacin</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Acemetacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13860</drugbank-id>
      <name>Imidazole salicylate</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Imidazole salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14059</drugbank-id>
      <name>SC-236</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with SC-236.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14060</drugbank-id>
      <name>NS-398</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with NS-398.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14938</drugbank-id>
      <name>Flurbiprofen axetil</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Flurbiprofen axetil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Flunisolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Betamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Triamcinolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Prednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Fludrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Hydrocortisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Prednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Methylprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Trilostane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Budesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Dexamethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Corticotropin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Cortisone acetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Paramethasone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Aldosterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Fluprednisolone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Meprednisone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Melengestrol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Deflazacort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Cortivazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Prednylidene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Cloprednol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The therapeutic efficacy of Mifamurtide can be decreased when used in combination with Cortisone.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-6</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.32e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>5.57</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>sodium (2R)-1-({2-[(2S)-2-[(4R)-4-carbamoyl-4-[(2S)-2-[(2R)-2-{[(2R,3R,4R,5R)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy}propanamido]propanamido]butanamido]propanamido]ethyl phosphono}oxy)-3-(hexadecanoyloxy)propan-2-yl hexadecanoate hydrate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>sodium (2R)-1-({2-[(2S)-2-[(4R)-4-carbamoyl-4-[(2S)-2-[(2R)-2-{[(2R,3R,4R,5R)-2-acetamido-4,5,6-trihydroxy-1-oxohexan-3-yl]oxy}propanamido]propanamido]butanamido]propanamido]ethyl phosphono}oxy)-3-(hexadecanoyloxy)propan-2-yl hexadecanoate hydrate</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>1277.515</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>1276.74102124</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>O.[Na+].CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCCNC(=O)[C@H](C)NC(=O)CC[C@@H](NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@@H]([C@H](O)[C@H](O)CO)[C@@H](NC(C)=O)C=O)C(N)=O)OC(=O)CCCCCCCCCCCCCCC</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C59H110N6NaO20P</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C59H109N6O19P.Na.H2O/c1-7-9-11-13-15-17-19-21-23-25-27-29-31-33-52(71)80-41-47(84-53(72)34-32-30-28-26-24-22-20-18-16-14-12-10-8-2)42-82-85(78,79)81-38-37-61-57(75)43(3)62-51(70)36-35-48(56(60)74)65-58(76)44(4)63-59(77)45(5)83-55(54(73)50(69)40-67)49(39-66)64-46(6)68;;/h39,43-45,47-50,54-55,67,69,73H,7-38,40-42H2,1-6H3,(H2,60,74)(H,61,75)(H,62,70)(H,63,77)(H,64,68)(H,65,76)(H,78,79);;1H2/q;+1;/p-1/t43-,44-,45+,47+,48+,49-,50+,54+,55+;;/m0../s1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>NGIYLSFJGRLEMI-MHTUOZSYSA-M</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>386.77</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>314.96</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>139.44</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>58</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>15</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>1.9</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>-3.5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>32700228</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Mifamurtide</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0002442</id>
      <name>Toll-like receptor 4</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A31744</ref-id>
            <pubmed-id>21226638</pubmed-id>
            <citation>Ando K, Mori K, Corradini N, Redini F, Heymann D: Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011 Feb;12(2):285-92. doi: 10.1517/14656566.2011.543129.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="O00206" source="Swiss-Prot">
        <name>Toll-like receptor 4</name>
        <general-function>Transmembrane signaling receptor activity</general-function>
        <specific-function>Cooperates with LY96 and CD14 to mediate the innate immune response to bacterial lipopolysaccharide (LPS). Acts via MYD88, TIRAP and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response (PubMed:9237759, PubMed:10835634). Also involved in LPS-independent inflammatory responses triggered by free fatty acids, such as palmitate, and Ni(2+). Responses triggered by Ni(2+) require non-conserved histidines and are, therefore, species-specific (PubMed:20711192). In complex with TLR6, promotes sterile inflammation in monocytes/macrophages in response to oxidized low-density lipoprotein (oxLDL) or amyloid-beta 42. In this context, the initial signal is provided by oxLDL- or amyloid-beta 42-binding to CD36. This event induces the formation of a heterodimer of TLR4 and TLR6, which is rapidly internalized and triggers inflammatory response, leading to the NF-kappa-B-dependent production of CXCL1, CXCL2 and CCL9 cytokines, via MYD88 signaling pathway, and CCL5 cytokine, via TICAM1 signaling pathway, as well as IL1B secretion. Binds electronegative LDL (LDL(-)) and mediates the cytokine release induced by LDL(-) (PubMed:23880187).</specific-function>
        <gene-name>TLR4</gene-name>
        <locus>9q32-q33</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>632-652</transmembrane-regions>
        <signal-regions>1-23</signal-regions>
        <theoretical-pi>6.26</theoretical-pi>
        <molecular-weight>95679.19</molecular-weight>
        <chromosome-location>9</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:11850</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>TLR4</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U93091</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O00206</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>TLR4_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hToll</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004795|Toll-like receptor 4
MMSASRLAGTLIPAMAFLSCVRPESWEPCVEVVPNITYQCMELNFYKIPDNLPFSTKNLD
LSFNPLRHLGSYSFFSFPELQVLDLSRCEIQTIEDGAYQSLSHLSTLILTGNPIQSLALG
AFSGLSSLQKLVAVETNLASLENFPIGHLKTLKELNVAHNLIQSFKLPEYFSNLTNLEHL
DLSSNKIQSIYCTDLRVLHQMPLLNLSLDLSLNPMNFIQPGAFKEIRLHKLTLRNNFDSL
NVMKTCIQGLAGLEVHRLVLGEFRNEGNLEKFDKSALEGLCNLTIEEFRLAYLDYYLDDI
IDLFNCLTNVSSFSLVSVTIERVKDFSYNFGWQHLELVNCKFGQFPTLKLKSLKRLTFTS
NKGGNAFSEVDLPSLEFLDLSRNGLSFKGCCSQSDFGTTSLKYLDLSFNGVITMSSNFLG
LEQLEHLDFQHSNLKQMSEFSVFLSLRNLIYLDISHTHTRVAFNGIFNGLSSLEVLKMAG
NSFQENFLPDIFTELRNLTFLDLSQCQLEQLSPTAFNSLSSLQVLNMSHNNFFSLDTFPY
KCLNSLQVLDYSLNHIMTSKKQELQHFPSSLAFLNLTQNDFACTCEHQSFLQWIKDQRQL
LVEVERMECATPSDKQGMPVLSLNITCQMNKTIIGVSVLSVLVVSVVAVLVYKFYFHLML
LAGCIKYGRGENIYDAFVIYSSQDEDWVRNELVKNLEEGVPPFQLCLHYRDFIPGVAIAA
NIIHEGFHKSRKVIVVVSQHFIQSRWCIFEYEIAQTWQFLSSRAGIIFIVLQKVEKTLLR
QQVELYRLLSRNTYLEWEDSVLGRHIFWRRLRKALLDGKSWNPEGTVGTGCNWQEATSI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0020616|Toll-like receptor 4 (TLR4)
ATGGAGCTGAATTTCTACAAAATCCCCGACAACCTCCCCTTCTCAACCAAGAACCTGGAC
CTGAGCTTTAATCCCCTGAGGCATTTAGGCAGCTATAGCTTCTTCAGTTTCCCAGAACTG
CAGGTGCTGGATTTATCCAGGTGTGAAATCCAGACAATTGAAGATGGGGCATATCAGAGC
CTAAGCCACCTCTCTACCTTAATATTGACAGGAAACCCCATCCAGAGTTTAGCCCTGGGA
GCCTTTTCTGGACTATCAAGTTTACAGAAGCTGGTGGCTGTGGAGACAAATCTAGCATCT
CTAGAGAACTTCCCCATTGGACATCTCAAAACTTTGAAAGAACTTAATGTGGCTCACAAT
CTTATCCAATCTTTCAAATTACCTGAGTATTTTTCTAATCTGACCAATCTAGAGCACTTG
GACCTTTCCAGCAACAAGATTCAAAGTATTTATTGCACAGACTTGCGGGTTCTACATCAA
ATGCCCCTACTCAATCTCTCTTTAGACCTGTCCCTGAACCCTATGAACTTTATCCAACCA
GGTGCATTTAAAGAAATTAGGCTTCATAAGCTGACTTTAAGAAATAATTTTGATAGTTTA
AATGTAATGAAAACTTGTATTCAAGGTCTGGCTGGTTTAGAAGTCCATCGTTTGGTTCTG
GGAGAATTTAGAAATGAAGGAAACTTGGAAAAGTTTGACAAATCTGCTCTAGAGGGCCTG
TGCAATTTGACCATTGAAGAATTCCGATTAGCATACTTAGACTACTACCTCGATGATATT
ATTGACTTATTTAATTGTTTGACAAATGTTTCTTCATTTTCCCTGGTGAGTGTGACTATT
GAAAGGGTAAAAGACTTTTCTTATAATTTCGGATGGCAACATTTAGAATTAGTTAACTGT
AAATTTGGACAGTTTCCCACATTGAAACTCAAATCTCTCAAAAGGCTTACTTTCACTTCC
AACAAAGGTGGGAATGCTTTTTCAGAAGTTGATCTACCAAGCCTTGAGTTTCTAGATCTC
AGTAGAAATGGCTTGAGTTTCAAAGGTTGCTGTTCTCAAAGTGATTTTGGGACAACCAGC
CTAAAGTATTTAGATCTGAGCTTCAATGGTGTTATTACCATGAGTTCAAACTTCTTGGGC
TTAGAACAACTAGAACATCTGGATTTCCAGCATTCCAATTTGAAACAAATGAGTGAGTTT
TCAGTATTCCTATCACTCAGAAACCTCATTTACCTTGACATTTCTCATACTCACACCAGA
GTTGCTTTCAATGGCATCTTCAATGGCTTGTCCAGTCTCGAAGTCTTGAAAATGGCTGGC
AATTCTTTCCAGGAAAACTTCCTTCCAGATATCTTCACAGAGCTGAGAAACTTGACCTTC
CTGGACCTCTCTCAGTGTCAACTGGAGCAGTTGTCTCCAACAGCATTTAACTCACTCTCC
AGTCTTCAGGTACTAAATATGAGCCACAACAACTTCTTTTCATTGGATACGTTTCCTTAT
AAGTGTCTGAACTCCCTCCAGGTTCTTGATTACAGTCTCAATCACATAATGACTTCCAAA
AAACAGGAACTACAGCATTTTCCAAGTAGTCTAGCTTTCTTAAATCTTACTCAGAATGAC
TTTGCTTGTACTTGTGAACACCAGAGTTTCCTGCAATGGATCAAGGACCAGAGGCAGCTC
TTGGTGGAAGTTGAACGAATGGAATGTGCAACACCTTCAGATAAGCAGGGCATGCCTGTG
CTGAGTTTGAATATCACCTGTCAGATGAATAAGACCATCATTGGTGTGTCGGTCCTCAGT
GTGCTTGTAGTATCTGTTGTAGCAGTTCTGGTCTATAAGTTCTATTTTCACCTGATGCTT
CTTGCTGGCTGCATAAAGTATGGTAGAGGTGAAAACATCTATGATGCCTTTGTTATCTAC
TCAAGCCAGGATGAGGACTGGGTAAGGAATGAGCTAGTAAAGAATTTAGAAGAAGGGGTG
CCTCCATTTCAGCTCTGCCTTCACTACAGAGACTTTATTCCCGGTGTGGCCATTGCTGCC
AACATCATCCATGAAGGTTTCCATAAAAGCCGAAAGGTGATTGTTGTGGTGTCCCAGCAC
TTCATCCAGAGCCGCTGGTGTATCTTTGAATATGAGATTGCTCAGACCTGGCAGTTTCTG
AGCAGTCGTGCTGGTATCATCTTCATTGTCCTGCAGAAGGTGGAGAAGACCCTGCTCAGG
CAGCAGGTGGAGCTGTACCGCCTTCTCAGCAGGAACACTTACCTGGAGTGGGAGGACAGT
GTCCTGGGGCGGCACATCTTCTGGAGACGACTCAGAAAAGCCCTGCTGGATGGTAAATCA
TGGAATCCAGAAGGAACAGTGGGTACAGGATGCAATTGGCAGGAAGCAACATCTATCTGA
</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01582</identifier>
            <name>TIR</name>
          </pfam>
          <pfam>
            <identifier>PF13855</identifier>
            <name>LRR_8</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endosome membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>external side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intrinsic component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lipopolysaccharide receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>perinuclear region of cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipopolysaccharide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipopolysaccharide receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>transmembrane signaling receptor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of cysteine-type endopeptidase activity involved in apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>B cell proliferation involved in immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to lipoteichoic acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to mechanical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to Gram-negative bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of fungus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>extrinsic apoptotic signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>I-kappaB kinase/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>I-kappaB phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interferon-gamma production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>interleukin-1 beta secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intestinal epithelial structure maintenance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipopolysaccharide-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>macrophage activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MyD88-dependent toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MyD88-independent toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interferon-gamma production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-17 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-23 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of interleukin-6 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of osteoclast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of tumor necrosis factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nitric oxide production involved in inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of B cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of chemokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gene expression</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-alpha production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-beta biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-beta production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interferon-gamma production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-1 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-10 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-12 biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-12 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-6 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-8 biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-8 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of JNK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of macrophage cytokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MHC class II biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric-oxide synthase biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NLRP3 inflammasome complex assembly</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nucleotide-binding oligomerization domain containing 1 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of platelet activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tumor necrosis factor biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tumor necrosis factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>programmed cell death</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of cytokine secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of dendritic cell cytokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T-helper 1 type immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 2 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 3 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 4 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor TLR1</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor TLR6</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>TRIF-dependent toll-like receptor signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0009323</id>
      <name>Nucleotide-binding oligomerization domain-containing protein 2</name>
      <organism>Humans</organism>
      <actions>
        <action>ligand</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A31744</ref-id>
            <pubmed-id>21226638</pubmed-id>
            <citation>Ando K, Mori K, Corradini N, Redini F, Heymann D: Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011 Feb;12(2):285-92. doi: 10.1517/14656566.2011.543129.</citation>
          </article>
          <article>
            <ref-id>A31745</ref-id>
            <pubmed-id>20596505</pubmed-id>
            <citation>Kager L, Potschger U, Bielack S: Review of mifamurtide in the treatment of patients with osteosarcoma. Ther Clin Risk Manag. 2010 Jun 24;6:279-86.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="Q9HC29" source="Swiss-Prot">
        <name>Nucleotide-binding oligomerization domain-containing protein 2</name>
        <general-function>Involved in gastrointestinal immunity. Upon stimulation by muramyl dipeptide (MDP), a fragment of bacterial peptidoglycan, binds the proximal adapter receptor-interacting RIPK2, which recruits ubiquitin ligases as XIAP, BIRC2, BIRC3, INAVA and the LUBAC complex, triggering activation of MAP kinases and activation of NF-kappa-B signaling. This in turn leads to the transcriptional activation of hundreds of genes involved in immune response. Required for MDP-induced NLRP1-dependent CASP1 activation and IL1B release in macrophages (PubMed:18511561).</general-function>
        <specific-function>Actin binding</specific-function>
        <gene-name>NOD2</gene-name>
        <locus>16q12.1</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>115281.675</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:5331</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1763</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9HC29</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>NOD2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>CARD15</synonym>
          <synonym>Caspase recruitment domain-containing protein 15</synonym>
          <synonym>IBD1</synonym>
          <synonym>Inflammatory bowel disease protein 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051572|Nucleotide-binding oligomerization domain-containing protein 2
MGEEGGSASHDEEERASVLLGHSPGCEMCSQEAFQAQRSQLVELLVSGSLEGFESVLDWL
LSWEVLSWEDYEGFHLLGQPLSHLARRLLDTVWNKGTWACQKLIAAAQEAQADSQSPKLH
GCWDPHSLHPARDLQSHRPAIVRRLHSHVENMLDLAWERGFVSQYECDEIRLPIFTPSQR
ARRLLDLATVKANGLAAFLLQHVQELPVPLALPLEAATCKKYMAKLRTTVSAQSRFLSTY
DGAETLCLEDIYTENVLEVWADVGMAGPPQKSPATLGLEELFSTPGHLNDDADTVLVVGE
AGSGKSTLLQRLHLLWAAGQDFQEFLFVFPFSCRQLQCMAKPLSVRTLLFEHCCWPDVGQ
EDIFQLLLDHPDRVLLTFDGFDEFKFRFTDRERHCSPTDPTSVQTLLFNLLQGNLLKNAR
KVVTSRPAAVSAFLRKYIRTEFNLKGFSEQGIELYLRKRHHEPGVADRLIRLLQETSALH
GLCHLPVFSWMVSKCHQELLLQEGGSPKTTTDMYLLILQHFLLHATPPDSASQGLGPSLL
RGRLPTLLHLGRLALWGLGMCCYVFSAQQLQAAQVSPDDISLGFLVRAKGVVPGSTAPLE
FLHITFQCFFAAFYLALSADVPPALLRHLFNCGRPGNSPMARLLPTMCIQASEGKDSSVA
ALLQKAEPHNLQITAAFLAGLLSREHWGLLAECQTSEKALLRRQACARWCLARSLRKHFH
SIPPAAPGEAKSVHAMPGFIWLIRSLYEMQEERLARKAARGLNVGHLKLTFCSVGPTECA
ALAFVLQHLRRPVALQLDYNSVGDIGVEQLLPCLGVCKALYLRDNNISDRGICKLIECAL
HCEQLQKLALFNNKLTDGCAHSMAKLLACRQNFLALRLGNNYITAAGAQVLAEGLRGNTS
LQFLGFWGNRVGDEGAQALAEALGDHQSLRWLSLVGNNIGSVGAQALALMLAKNVMLEEL
CLEENHLQDEGVCSLAEGLKKNSSLKILKLSNNCITYLGAEALLQALERNDTILEVWLRG
NTFSLEEVDKLGCRDTRLLL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051573|Nucleotide-binding oligomerization domain-containing protein 2 (NOD2)
ATGGGGGAAGAGGGTGGTTCAGCCTCTCACGATGAGGAGGAAAGAGCAAGTGTCCTCCTC
GGACATTCTCCGGGTTGTGAAATGTGCTCGCAGGAGGCTTTTCAGGCACAGAGGAGCCAG
CTGGTCGAGCTGCTGGTCTCAGGGTCCCTGGAAGGCTTCGAGAGTGTCCTGGACTGGCTG
CTGTCCTGGGAGGTCCTCTCCTGGGAGGACTACGAGGGCTTCCACCTCCTGGGCCAGCCT
CTCTCCCACTTGGCCAGGCGCCTTCTGGACACCGTCTGGAATAAGGGTACTTGGGCCTGT
CAGAAGCTCATCGCGGCTGCCCAAGAAGCCCAGGCCGACAGCCAGTCCCCCAAGCTGCAT
GGCTGCTGGGACCCCCACTCGCTCCACCCAGCCCGAGACCTGCAGAGTCACCGGCCAGCC
ATTGTCAGGAGGCTCCACAGCCATGTGGAGAACATGCTGGACCTGGCATGGGAGCGGGGT
TTCGTCAGCCAGTATGAATGTGATGAAATCAGGTTGCCGATCTTCACACCGTCCCAGAGG
GCAAGAAGGCTGCTTGATCTTGCCACGGTGAAAGCGAATGGATTGGCTGCCTTCCTTCTA
CAACATGTTCAGGAATTACCAGTCCCATTGGCCCTGCCTTTGGAAGCTGCCACATGCAAG
AAGTATATGGCCAAGCTGAGGACCACGGTGTCTGCTCAGTCTCGCTTCCTCAGTACCTAT
GATGGAGCAGAGACGCTCTGCCTGGAGGACATATACACAGAGAATGTCCTGGAGGTCTGG
GCAGATGTGGGCATGGCTGGACCCCCGCAGAAGAGCCCAGCCACCCTGGGCCTGGAGGAG
CTCTTCAGCACCCCTGGCCACCTCAATGACGATGCGGACACTGTGCTGGTGGTGGGTGAG
GCGGGCAGTGGCAAGAGCACGCTCCTGCAGCGGCTGCACTTGCTGTGGGCTGCAGGGCAA
GACTTCCAGGAATTTCTCTTTGTCTTCCCATTCAGCTGCCGGCAGCTGCAGTGCATGGCC
AAACCACTCTCTGTGCGGACTCTACTCTTTGAGCACTGCTGTTGGCCTGATGTTGGTCAA
GAAGACATCTTCCAGTTACTCCTTGACCACCCTGACCGTGTCCTGTTAACCTTTGATGGC
TTTGACGAGTTCAAGTTCAGGTTCACGGATCGTGAACGCCACTGCTCCCCGACCGACCCC
ACCTCTGTCCAGACCCTGCTCTTCAACCTTCTGCAGGGCAACCTGCTGAAGAATGCCCGC
AAGGTGGTGACCAGCCGTCCGGCCGCTGTGTCGGCGTTCCTCAGGAAGTACATCCGCACC
GAGTTCAACCTCAAGGGCTTCTCTGAACAGGGCATCGAGCTGTACCTGAGGAAGCGCCAT
CATGAGCCCGGGGTGGCGGACCGCCTCATCCGCCTGCTCCAAGAGACCTCAGCCCTGCAC
GGTTTGTGCCACCTGCCTGTCTTCTCATGGATGGTGTCCAAATGCCACCAGGAACTGTTG
CTGCAGGAGGGGGGGTCCCCAAAGACCACTACAGATATGTACCTGCTGATTCTGCAGCAT
TTTCTGCTGCATGCCACCCCCCCAGACTCAGCTTCCCAAGGTCTGGGACCCAGTCTTCTT
CGGGGCCGCCTCCCCACCCTCCTGCACCTGGGCAGACTGGCTCTGTGGGGCCTGGGCATG
TGCTGCTACGTGTTCTCAGCCCAGCAGCTCCAGGCAGCACAGGTCAGCCCTGATGACATT
TCTCTTGGCTTCCTGGTGCGTGCCAAAGGTGTCGTGCCAGGGAGTACGGCGCCCCTGGAA
TTCCTTCACATCACTTTCCAGTGCTTCTTTGCCGCGTTCTACCTGGCACTCAGTGCTGAT
GTGCCACCAGCTTTGCTCAGACACCTCTTCAATTGTGGCAGGCCAGGCAACTCACCAATG
GCCAGGCTCCTGCCCACGATGTGCATCCAGGCCTCGGAGGGAAAGGACAGCAGCGTGGCA
GCTTTGCTGCAGAAGGCCGAGCCGCACAACCTTCAGATCACAGCAGCCTTCCTGGCAGGG
CTGTTGTCCCGGGAGCACTGGGGCCTGCTGGCTGAGTGCCAGACATCTGAGAAGGCCCTG
CTCCGGCGCCAGGCCTGTGCCCGCTGGTGTCTGGCCCGCAGCCTCCGCAAGCACTTCCAC
TCCATCCCGCCAGCTGCACCGGGTGAGGCCAAGAGCGTGCATGCCATGCCCGGGTTCATC
TGGCTCATCCGGAGCCTGTACGAGATGCAGGAGGAGCGGCTGGCTCGGAAGGCTGCACGT
GGCCTGAATGTTGGGCACCTCAAGTTGACATTTTGCAGTGTGGGCCCCACTGAGTGTGCT
GCCCTGGCCTTTGTGCTGCAGCACCTCCGGCGGCCCGTGGCCCTGCAGCTGGACTACAAC
TCTGTGGGTGACATTGGCGTGGAGCAGCTGCTGCCTTGCCTTGGTGTCTGCAAGGCTCTG
TATTTGCGCGATAACAATATCTCAGACCGAGGCATCTGCAAGCTCATTGAATGTGCTCTT
CACTGCGAGCAATTGCAGAAGTTAGCTCTATTCAACAACAAATTGACTGACGGCTGTGCA
CACTCCATGGCTAAGCTCCTTGCATGCAGGCAGAACTTCTTGGCATTGAGGCTGGGGAAT
AACTACATCACTGCCGCGGGAGCCCAAGTGCTGGCCGAGGGGCTCCGAGGCAACACCTCC
TTGCAGTTCCTGGGATTCTGGGGCAACAGAGTGGGTGACGAGGGGGCCCAGGCCCTGGCT
GAAGCCTTGGGTGATCACCAGAGCTTGAGGTGGCTCAGCCTGGTGGGGAACAACATTGGC
AGTGTGGGTGCCCAAGCCTTGGCACTGATGCTGGCAAAGAACGTCATGCTAGAAGAACTC
TGCCTGGAGGAGAACCATCTCCAGGATGAAGGTGTATGTTCTCTCGCAGAAGGACTGAAG
AAAAATTCAAGTTTGAAAATCCTGAAGTTGTCCAATAACTGCATCACCTACCTAGGGGCA
GAAGCCCTCCTGCAGGCCCTTGAAAGGAATGACACCATCCTGGAAGTCTGGCTCCGAGGG
AACACTTTCTCTCTAGAGGAGGTTGACAAGCTCGGCTGCAGGGACACCAGACTCTTGCTT
TGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00619</identifier>
            <name>CARD</name>
          </pfam>
          <pfam>
            <identifier>PF13516</identifier>
            <name>LRR_6</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>basolateral plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cell surface</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoskeleton</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>Golgi apparatus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>actin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>CARD domain binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>Hsp70 protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>Hsp90 protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>muramyl dipeptide binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peptidoglycan binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>activation of MAPK activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to muramyl dipeptide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to organic cyclic compound</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to peptidoglycan</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytokine production involved in immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cytokine secretion involved in immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of bacterium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of biotic stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>detection of muramyl dipeptide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>intracellular signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>JNK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of gastrointestinal epithelium</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of macrophage apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleotide-binding oligomerization domain containing 2 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleotide-binding oligomerization domain containing signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of B cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cytokine production involved in inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of dendritic cell antigen processing and presentation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of dendritic cell cytokine production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of epithelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of ERK1 and ERK2 cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of gamma-delta T cell activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of I-kappaB kinase/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-1 beta production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-1 beta secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-10 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-17 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-6 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of interleukin-8 production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of JNK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of MAP kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NIK/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric-oxide synthase biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of Notch signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of phosphatidylinositol 3-kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of prostaglandin-E synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of prostaglandin-endoperoxide synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of protein K63-linked ubiquitination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of stress-activated MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of tumor necrosis factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of type 2 immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein deubiquitination</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein oligomerization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to muramyl dipeptide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes/>
  <carriers/>
  <transporters/>
</drug>